Search results for " Pharmaceutical"

showing 9 items of 409 documents

S2k guidelines for the treatment of psoriasis in children and adolescents - Short version part 2.

2019

The present guidelines are aimed at residents and board-certified physicians in the fields of dermatology, pediatrics, pediatric dermatology and pediatric rheumatology as well as policymakers and insurance funds. They were developed by dermatologists and pediatric dermatologists in collaboration with pediatric rheumatologists using a formal consensus process (S2k). The guidelines highlight topics such as disease severity, quality of life, treatment goals as well as problems associated with off-label drug therapy in children. Trigger factors and diagnostic aspects are discussed. The primary focus is on the various topical, systemic and UV-based treatment options available and includes recomm…

medicine.medical_specialtyTuberculosisAdolescentMEDLINEDermatologyDiseaseDrug Administration Schedule030207 dermatology & venereal diseases03 medical and health sciencesPsoriatic arthritisBiological Factors0302 clinical medicinePharmacotherapyQuality of life (healthcare)PsoriasismedicineHumansPsoriasisChildBiosimilar PharmaceuticalsTonsillectomybusiness.industryVaccinationmedicine.diseaseSkin CareAnti-Bacterial AgentsFamily medicineUltraviolet TherapyDermatologic AgentsbusinessGuttate psoriasisImmunosuppressive AgentsJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDGReferences
researchProduct

Media-fill simulation tests in manual and robotic aseptic preparation of injection solutions in syringes

2014

Objective The purpose of this study was to evaluate the contamination rate of media-fill products either prepared automated with a robotic system (APOTECAchemo™) or prepared manually at cytotoxic workbenches in the same cleanroom environment and by experienced operators. Media fills were completed by microbiological environmental control in the critical zones and used to validate the cleaning and disinfection procedures of the robotic system. Methods The aseptic preparation of patient individual ready-to-use injection solutions was simulated by using double concentrated tryptic soy broth as growth medium, water for injection and plastic syringes as primary packaging materials. Media fills w…

medicine.medical_specialtybusiness.industrySyringesRoboticsCleaning validation030226 pharmacology & pharmacySurgeryPharmaceutical Solutions03 medical and health sciencesContamination rate0302 clinical medicineRobotic systemsOncologyTechnology PharmaceuticalMedicinePharmacology (medical)030212 general & internal medicineAseptic processingDrug ContaminationbusinessAsepsisBiomedical engineeringJournal of Oncology Pharmacy Practice
researchProduct

Resistin: An Inflammatory Cytokine. Role in Cardiovascular Diseases, Diabetes and the Metabolic Syndrome

2014

Resistin is an adipocyte- and monocyte-derived cytokine which has been implicated in the modulation of insulin action, energy, glucose and lipid homeostasis. Resistin has been associated with insulin resistance and many of its known complications. As a molecular link between metabolic signals, inflammation, and vascular dysfunction, resistin can be proposed as playing a significant role in the heightened inflammatory state induced by metabolic stress linked to excessive caloric intake, thus contributing to the risk for metabolic syndrome (MetS), type 2 diabetes (T2DM), and cardiovascular diseases (CVD). In this review, we highlighted the role of resistin, as an inflammatory cytokine, in the…

medicine.medical_specialtyendocrine system diseasesmedicine.medical_treatmentInflammationType 2 diabetesModels BiologicalType 2 diabetemetabolic syndrome03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInsulin resistanceAdipocyteInternal medicineDiabetes mellitusDrug DiscoverymedicineHumansResistin030304 developmental biologyMetabolic SyndromePharmacology0303 health sciencesbusiness.industryDrug Discovery3003 Pharmaceutical ScienceMedicine (all)Insulinnutritional and metabolic diseasesCardiovascular diseasemedicine.disease3. Good healthcardiovascular diseasesEndocrinologyDiabetes Mellitus Type 2chemistryCardiovascular Diseases030220 oncology & carcinogenesisImmunologyResistintype 2 diabetesInflammation MediatorsMetabolic syndromemedicine.symptombusinesshormones hormone substitutes and hormone antagonists
researchProduct

Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardio…

2021

Abstract Aims In breast cancer (BC) patients treated with anthracyclines-based therapies, we aim at assessing whether adjuvant drugs impact cardiac function differently and whether their cardiotoxicity has a regional pattern. Methods and results In a multicentre study, 146 BC patients (56 ± 11 years) were prospectively enrolled and divided into three groups according to the received treatments: AC/EC-Group (doxorubicin or epirubicin + cyclophosphamide), AC/EC/Tax-Group (AC/EC + taxanes), FEC/Tax-Group (fluorouracil + EC + taxanes). Fifty-six patients of the total cohort also received trastuzumab. Left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) were calculated …

medicine.medical_specialtymedicine.medical_treatmentPopulationCardiologyBreast NeoplasmsAnthracyclineAnthracyclines; Breast cancer; Cardiotoxicity; Myocardial strain030204 cardiovascular system & hematologyAnthracyclines Breast cancer Breast Neoplasms Cardiology Cardiotoxicity Echocardiography Female Humans italy Myocardial strain Pharmaceutical Preparations Stroke Volume Trastuzumab Ventricular Function Left Ventricular Dysfunction LeftVentricular Function LeftVentricular Dysfunction Left03 medical and health sciencesBreast cancer0302 clinical medicineTrastuzumabInternal medicineHumansMedicineAnthracyclinesRadiology Nuclear Medicine and imagingeducationeducation.field_of_studyChemotherapyCardiotoxicityEjection fractionbusiness.industryStroke VolumeGeneral MedicineTrastuzumabMyocardial strainChemotherapy regimenCardiotoxicityItalyPharmaceutical PreparationsEchocardiographyFluorouracil030220 oncology & carcinogenesisCardiologyFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugEpirubicinEuropean Heart Journal - Cardiovascular Imaging
researchProduct

Does anti-inflammatory drugs modify the severe odontogenic infection prognosis? A 10-year’s experience

2020

Background Numerous biochemical datas support the noxious role of anti-inflammatory drugs on immune response. Those observations are often put forward for unfavorable evolution of odontogenic infection but has never been really proven in clinic. The aim of this study is to try to clarify this role based on the collection of the clinical course of odontogenic infections over a 10-year analysis period. Material and Methods The investigators implemented a prospective observational study. The sample was composed of patients managed between January 2004 and December 2014 for severe odontogenic infection based on three criteria: hospital admission, intravenous antibiotic therapy, tooth extraction…

medicine.medical_specialtytumorErythemamedicine.drug_classMESH: Pharmaceutical PreparationsPopulationAnti-Inflammatory AgentsPaincarcinomaMESH: Prognosislip03 medical and health sciences0302 clinical medicine[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesInternal medicinemedicineHumanseducationGeneral DentistryUNESCO:CIENCIAS MÉDICASOdontogenic infectioncystUnivariate analysiseducation.field_of_studyMESH: Humansbusiness.industryResearchAnti-Inflammatory Agents Non-Steroidal030206 dentistrymedicine.diseasePrognosisMESH: Anti-Inflammatory Agents Non-SteroidalOtorhinolaryngologyPharmaceutical PreparationsMESH: Anti-Inflammatory AgentsPropensity score matching[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesCorticosteroidSurgeryObservational studyMESH: Painmedicine.symptomOral SurgerybusinessOdynophagianeoplasm
researchProduct

Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario.

2015

Abstract: Introduction: The identification of cell membrane-bound molecules with a relevant role in cancer cell survival prompted the development of moAbs to block the related pathways. In the last few years, the number of approved moAbs for cancer treatment has constantly increased. Many of these drugs significantly improved the survival outcomes in patients with solid tumours. Areas covered: In this review, all the FDA-approved moAbs in solid tumours have been described. This is an update of moAbs available for cancer treatment nowadays in comparison with the moAbs approved until few years ago. The moAbs under development are also discussed here. Expert opinion: The research on cancer ant…

medicine.medical_treatmentClinical BiochemistryCellReceptor activator of nuclear factor κB ligandCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)NeoplasmsMonoclonalDrug DiscoveryDrug approvalCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all); Cancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)Drug ApprovalCancerbiologyMedicine (all)Antibodies MonoclonalVEGFReceptor activator of nuclear factor κB ligandmedicine.anatomical_structureMonoclonalMoAbsImmunotherapyAntibodyEngineering sciences. TechnologyHumanUnited StateCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)medicine.drug_classEGFRMonoclonal antibodyAntibodiesCancer antigenCytotoxic T-lymphocyte antigen 4HER2medicineHumansBiologyPharmacologybusiness.industryUnited States Food and Drug AdministrationDrug Discovery3003 Pharmaceutical ScienceCancerImmunotherapymedicine.diseaseUnited StatesImmunologyCancer cellCancer researchbiology.proteinNeoplasmMoAbHuman medicinebusinessExpert opinion on biological therapy
researchProduct

Optimization of Spray-Drying Process of

2019

Jerusalem artichoke is an important natural matrix for inulin production. In this experiment, response surface methodology (RSM) was employed to optimize the spray-drying parameters in order to determine the maximal inulin yield. For this study, three independent variables (heating temperature (Tª, 110–120 °C), creep speed (V, 18–22 rpm) and pressure (P, 0.02–0.04 MPa)) were used in the experimental design. Using the Box–Behnken design, the optimal parameters obtained were: drying temperature 114.6 °C, creep speed 20.02 rpm, and pressure: 0.03 MPa. The inulin yield, water content and particle size of inulin obtained by spray-drying and freeze-drying were compared. In this regard, the spray-…

response surface methodologyFreeze DryinginulinPlant ExtractsChemistry PharmaceuticalJerusalem artichokeHelianthusspray-dryingPowdersArticleMolecules (Basel, Switzerland)
researchProduct

Synthesis, antiproliferative activity, and in silico insights of new 3-benzoylamino-benzo[ b ]thiophene derivatives

2014

A new series of 3-benzoylamino-5-imidazol-5-yl-benzo[b]thiophenes and the parent amino derivatives were synthesized and screened as antitumor agents. All tested compounds showed concentration-dependent antiproliferative activity profile against HeLa cell line, exhibiting GI50 values in the low micromolar range. The most active compounds were tested in cell cycle perturbation experiments. A rapid accumulation of cells in the G2/M phase, with a concomitant reduction of cells in both the S and G0/G1 phases, was observed, suggesting that cell exposure to selected derivatives produces mitotic failure. To rationalize the biological results, the 3-benzoylamino-benzo[b]thiophenes were analyzed thro…

thiopheneVLAK protocolStereochemistryIn silicoCellAntineoplastic AgentsMechanism of actionHeLa CellHeLaAntineoplastic AgentStructure-Activity Relationship3-Benzoylamino-5-imidazol-4-yl-benzo[b]Settore BIO/10 - BiochimicaDrug DiscoverymedicineHumansMoietyComputer SimulationMitosisCell ProliferationPharmacologyAntitumor agentsbiologyDose-Response Relationship DrugMolecular StructureChemistryDrug Discovery3003 Pharmaceutical ScienceMedicine (all)Cell CycleOrganic ChemistryAntitumor agentG2/M phaseGeneral MedicineSettore CHIM/06 - Chimica OrganicaHeLa cell linebiology.organism_classificationSettore CHIM/08 - Chimica Farmaceuticamedicine.anatomical_structureCell cultureSettore CHIM/03 - Chimica Generale E InorganicathiophenesAntimitotic AgentTopoisomerase-II InhibitorDrug Screening Assays AntitumorHeLa CellsHuman
researchProduct

Chemical Composition of the Essential Oil of Bupleurum Fontanesii (Apiaceae) Growing Wild in Sicily and its Activity on Microorganisms Affecting Hist…

2016

Hydrodistillation of the flowers (BpFl) of and fruits (BpFr) of Bupleurum fontanesii Guss. ex Caruel gave two oils that were analyzed by GC and GC-MS. The main components were α-elemol (16.7%), caryophyllene oxide (16.4%) and heptacosane (15.9%) in BpFl, and spathulenol (16.8%), caryophylladienol I (13.2%) and α-elemol (12.8%) in BpFr. A good antimicrobial activity against several microorganisms, including Bacillus subtilis, Staphylococcus aureus, Fusarium oxysporum and Aspergillus niger, all infesting historical art craft, was also determined.

α-ElemolBupleurumAntifungal AgentsMicroorganismPlant ScienceBacillus subtilis01 natural scienceslaw.inventionlawVolatile componentDrug DiscoveryBotanyFusarium oxysporumOils VolatilePlant OilsSicilyEssential oilPharmacologyApiaceaeBacteriaBupleurum fontanesiibiology010405 organic chemistryDrug Discovery3003 Pharmaceutical ScienceAspergillus nigerFungiSpathulenolfood and beveragesGeneral MedicineComplementary and Alternative Medicine2708 DermatologyAntimicrobialbiology.organism_classificationAnti-Bacterial AgentsBupleurum0104 chemical sciences010404 medicinal & biomolecular chemistryCaryophyllene oxideComplementary and alternative medicineArtApiaceaeNatural Product Communications
researchProduct